Protalex, Inc. (fkaPRTX)

[thee trader]

Latest PR - PROTALEX, INC. TO PRESENT AT RODMAN & RENSHAW 10TH ANNUAL HEALTHCARE CONFERENCE

NEW HOPE, Pa., Nov 03, 2008 (BUSINESS WIRE) -- Protalex, Inc. (OTCBB:PRTX) today announced that Steven H. Kane, President and Chief Executive Officer, will present at the upcoming Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 3:40 p.m. Eastern Time. The event will be held from November 10-12, 2008 at the New York Palace Hotel in New York.

Individuals may listen to a live webcast of the presentation by logging on to the Investors section of Protalex' web site, www.protalex.net, a few minutes prior to start time. The presentation will be archived for 90 days.

The conference will feature presentations from more than 350 public and privately held emerging growth healthcare companies presenting data on an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology. Details regarding the conference can be obtained at www.rodmanandrenshaw.com.

About PRTX-100

PRTX-100 is a highly-purified form of the Staphylococcal bacterial protein known as Protein A. PRTX-100 has the ability, at very low concentrations, to bind to and to down regulate activation of human B-lymphocytes and macrophages which are key cells mediating inflammation in certain autoimmune diseases. Laboratory studies indicate the mechanism involves interference with specific intracellular signaling pathways. Pre-clinical studies also demonstrate that very low doses of PRTX-100 have potent therapeutic effects on model inflammatory diseases.

About Protalex, Inc.

Protalex, Inc. is a biotechnology company engaged in the development of a new class of drugs for the treatment of rheumatoid arthritis, idiopathic thrombocytopenic purpura and a host of other autoimmune disorders. Additional information about Protalex, Inc. can be found at www.protalex.com.

Cautionary Statement Regarding Forward Looking Information

This release contains forward-looking information about Protalex, Inc. that are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and Protalex's future performance, operations and products.

This forward-looking information should be considered only in connection with "Risk Factors" in Protalex's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on August 29, 2008 and its other periodic reports filed with the SEC. Protalex assumes no obligation to update any forward-looking statements or information set forth in this press release.

PRTX-G

SOURCE: Protalex, Inc.

Protalex, Inc.
Marc L. Rose
Vice President and Chief Financial Officer
(p) 215-862-9720
(f) 215-862-6614
[e-mail]

Copyright Business Wire 2008

News Provided by COMTEX

http://investor.protalex.com/ReleaseDetail.cfm?ReleaseID=345020